RxDoctor Payments Data

William Rosenblatt, MD

Internal Medicine · Columbus, MSNPI 1881038842

Payments from drug & device makers

$310in general payments, 2019–2025

Across 9 payments — averaging $34.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$133
  • Boston Scientific$60
  • Johnson & Johnson$33
  • BD$31
  • Dexcom, Inc.$28
  • Pfizer$25

What the payments were for

  • Food & beverage$310100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic1$133
Boston Scientific2$60
Johnson & Johnson2$33
BD1$31
Dexcom, Inc.1$28
Pfizer2$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$310 in reported general payments places this provider in the 40th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$299,058
Medicare patients
617
Services billed
5,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide265$353,880
JardianceEmpagliflozin181$193,925
MounjaroTirzepatide117$129,869
EliquisApixaban96$93,757
Xigduo XrDapaglifloz Propaned/Metformin41$39,246
JanuviaSitagliptin Phosphate23$28,605
FarxigaDapagliflozin Propanediol25$27,223
Tresiba Flextouch U-100Insulin Degludec28$24,692
Incruse ElliptaUmeclidinium Bromide59$20,343
Victoza 3-PakLiraglutide20$16,363
ZenpepLipase/Protease/Amylase11$15,755
FycompaPerampanel12$15,684
TrulicityDulaglutide12$14,189
Lantus SolostarInsulin Glargine,hum.Rec.Anlog83$13,487
Novolog FlexpenInsulin Aspart66$12,605

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$93,75796 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Columbus

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →